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Considerable evidence indicates that the metabolite of ethanol (EtOH), acetaldehyde,
is biologically active. Acetaldehyde can be formed from EtOH peripherally mainly by
alcohol dehydrogenase (ADH), and also centrally by catalase. EtOH and acetaldehyde
show differences in their behavioral effects depending upon the route of administration.
In terms of their effects on motor activity and motivated behaviors, when administered
peripherally acetaldehyde tends to be more potent than EtOH but shows very similar
potency administered centrally. Since dopamine (DA) rich areas have an important role
in regulating both motor activity and motivation, the present studies were undertaken
to compare the effects of central (intraventricular, ICV) and peripheral (intraperitoneal,
IP) administration of EtOH and acetaldehyde on a cellular marker of brain activity, c-Fos
immunoreactivity, in DA innervated areas. Male Sprague-Dawley rats received an IP
injection of vehicle, EtOH (0.5 or 2.5 g/kg) or acetaldehyde (0.1 or 0.5 g/kg) or an ICV
injection of vehicle, EtOH or acetaldehyde (2.8 or 14.0µmoles). IP administration of EtOH
minimally induced c-Fos in some regions of the prefrontal cortex and basal ganglia, mainly
at the low dose (0.5 g/kg), while IP acetaldehyde induced c-Fos in virtually all the structures
studied at both doses. Acetaldehyde administered centrally increased c-Fos in all areas
studied, a pattern that was very similar to EtOH. Thus, IP administered acetaldehyde was
more efficacious than EtOH at inducing c-Fos expression. However, the general pattern
of c-Fos induction promoted by ICV EtOH and acetaldehyde was similar. These results
are consistent with the pattern observed in behavioral studies in which both substances
produced the same magnitude of effect when injected centrally, and produced differences
in potency after peripheral administration.
Keywords: alcohol, metabolism, early gene, nucleus accumbens, dopamine
INTRODUCTION
Ethanol (EtOH) is converted into acetaldehyde in many organs by
the enzyme alcohol dehydrogenase (ADH) (Cohen et al., 1980).
Acetaldehyde is then metabolized to acetate by aldehyde dehydro-
genase (ALDH) (Svanas and Weiner, 1985; Deng and Deitrich,
2008). EtOH crosses the blood brain barrier and is found in
peripheral organs as well as in the brain (Eriksson and Sippel,
1977; Deitrich, 1987; Zimatkin, 1991). However, acetaldehyde
cannot easily cross into the brain because of the abundance
Abbreviations: AcbC, accumbens core; AcbSh, accumbens shell; ADH, alcohol
dehydrogenase; ALDH, aldehyde dehydrogenase; aCSF, artificial cerebrospinal
fluid; ac, anterior commissure; BLA, basolateral amygdala; CA1, CA1 of the hip-
pocampus; CeA, central amygdala; Cg1, cingulate cortex 1; cc, corpus callosum;
DG, dentate gyrus; DA, dopamine; DLS, dorsolateral striatum; DMS, dorsomedial
striatum; EtOH, ethanol; ERK, extracellular regulated kinase; VLS, ventrolateral
striatum; IL, infralimbic cortex; IP, intraperitoneal; ICV, intraventricular; LS, lateral
septum; O, orbitofrontal cortex; HPV, paraventricular nuclei of the hypothalamus;
PVTh, paraventricular nuclei of the thalamus; PrL, prelimbic cortex; Tu, lateral
tubercle; VP, ventral pallidum.
of ALDH in capillary endothelium and surrounding astrocytes
of the blood brain barrier (Sippel, 1974; Westcott et al., 1980;
Zimatkin, 1991). Only when blood acetaldehyde levels are raised
after ALDH blockade, significant amounts of acetaldehyde cross
into the brain. In addition, an alternative source of acetaldehyde
in the brain is the local intracerebral metabolism of EtOH by the
enzyme catalase (Cohen et al., 1980; Aragon et al., 1992; Correa
et al., 2012).
EtOH and acetaldehyde do not always have the same pattern
of effects on behavior (for a review see Correa et al., 2012). For
instance, in rats they produce similar effects on motor activi-
ties such as locomotion, and on motivated behaviors such as
lever pressing for food in different reinforcement conditions;
both exert suppressant effects when peripherally administered
(Chuck et al., 2006; McLaughlin et al., 2008), and activating
effects when administered in the brain (Arizzi et al., 2003; Correa
et al., 2003a,b, 2009a; Arizzi-LaFrance et al., 2006; McLaughlin
et al., 2008; Pastor and Aragon, 2008). Yet while the relative
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efficacy and potency of both substances is very similar after
central administration, they are very different after peripheral
administration to both rats and mice (Correa et al., 2004, 2009b;
Tambour et al., 2005; Chuck et al., 2006; McLaughlin et al., 2008;
Closon et al., 2009; Escrig et al., 2012); peripherally acetaldehyde
seems always more potent than EtOH.
The induction of Fos/Jun family transcription factors has been
widely used as a tool to show neuronal activation in response to a
wide range of stimuli (Curran and Morgan, 1995). EtOH expo-
sure through different routes of administration induces early-
gene protein expression in several brain regions (Chang et al.,
1995; Ogilvie et al., 1998; Bachtell et al., 1999, 2002; Thiele et al.,
2000; Knapp et al., 2001; Crankshaw et al., 2003; Canales, 2004),
and such expression reflects specific activation of intracellular
pathways (Curran and Morgan, 1995; Thiele et al., 2000; Ibba
et al., 2009). For instance, c-Fos protein expression is modulated
after dopamine (DA) receptor signaling in neurons receiving DA
input (Moratalla et al., 1992; Nguyen et al., 1992; Farrar et al.,
2010; Pardo et al., 2012, 2013; Segovia et al., 2012). EtOH, as
well as acetaldehyde, have been demonstrated to regulate DA
release in some of these areas (Di Chiara and Imperato, 1986;
Acquas et al., 1993; Melis et al., 2007; Bustamante et al., 2008;
Enrico et al., 2009; Sirca et al., 2011). However, very few stud-
ies have assessed the effect of acetaldehyde on c-Fos protein
expression. Thus, expression of c-Fos mRNA after intravenous
administration of a low dose of acetaldehyde was only induced
in the paraventricular nuclei of the thalamus (PVTh) (Cao et al.,
2007). In another study, blood acetaldehyde accumulated after
intraperitoneal (IP) coadministration of EtOH and cyanamide
(an ALDH inhibitor; Kinoshita et al., 2002), resulted in a signifi-
cant increase in c-Fos mRNA in the paraventricular nuclei of the
hypothalamus (HPV) (Kinoshita et al., 2002). Thus, it seems that
peripheral acetaldehyde accumulation, by direct administration
or by blockade of its degradation, results in c-FosmRNA increases
in some brain nuclei (Kinoshita et al., 2002; Cao et al., 2007).
However, inhibition of brain catalase activity with aminotriazole
did not alter EtOH evoked dose-dependent increases in c-Fos
inmunoreactivity in several brain regions (Canales, 2004). This
lack of effect after the blockade of centrally generated acetalde-
hyde could lead to the suggestion that in the brain, only EtOH
triggers this neuronal marker. However, no study thus far has
investigated the effect of acetaldehyde increases in the brain on
c-Fos immunoreactivity.
In the present study we assessed the pattern of c-Fos expres-
sion after peripheral (IP) or central (intraventricular, ICV)
EtOH and acetaldehyde administration. We analyzed a broad
range of prefrontal, basal ganglia and limbic system areas,
most of which receive a substantial DA innervation (Fallon
and Moore, 1978; Fields, 2007; Ikemoto, 2007), and we used
doses of both substances that have been demonstrated to mod-
ulate several motor activities and motivated behaviors (Arizzi
et al., 2003; Correa et al., 2003a,b; Arizzi-LaFrance et al.,
2006; Chuck et al., 2006; McLaughlin et al., 2008) regu-
lated by DA. Peripherally we also administered higher doses
of acetaldehyde than the ones used in behavioral studies in
order to make additional direct comparisons between EtOH and
acetaldehyde.
METHODS
SUBJECTS
Male Sprague-Dawley rats (290–320 g;N = 45) (Harlan Sprague-
Dawley, Indianapolis, IN) were housed in a colony maintained at
23◦C with a 12 L: 12 D cycle (lights on at 7 h). Water and food
were available ad libitum in the home cages. In order to minimize
the possible effects of receiving a novel potentially stressful injec-
tion, rats were handled for 5 days prior to drug administration.
For the ICV experiment, the handling was done after recovery
from surgery. All animals received humane care in compliance
with the protocols approved by the University of Connecticut
Institutional Animal Care and Use Committee, and the studies
have been conducted according to National Institute of Health
Guide for the care and use of animals, National Academy Press
(1996) and the EC Directive 86/609/EEC.
DRUGS
EtOH [100%, 200 proof, USP (United States Pharmacopea);
AAPER Alcohol and Chemical Co.], acetaldehyde (Fisher
Scientific) were dissolved in physiological saline (0.9% w/v) for
IP administration and in artificial cerebrospinal fluid (aCSF)
for the ICV administration. The aCSF was prepared by mix-
ing sodium chloride, potassium chloride and calcium chloride
(147.2mM NaCl, 2.4mM CaCl2, 4.0mM KCl) in purified water.
For IP injections, the stock solutions from which the different
doses were obtained were: EtOH 20% v/v and acetaldehyde 2%
v/v. The doses were 0.5 and 2.5 g/kg of EtOH or 0.1 and 0.5 g/kg
acetaldehyde. The two IP doses of EtOH and the lower dose of
acetaldehyde were selected based on previous behavioral stud-
ies (Chuck et al., 2006; McLaughlin et al., 2008) and the higher
dose of acetaldehyde (0.5 g/kg) was selected in order to compare
it with the same dose of EtOH. For the ICV studies, EtOH and
acetaldehyde were injected at doses of 2.8 and 14.0µmoles (solu-
tions were 16% and 80% v/v, respectively), in 1.0µl total volume
(EtOH: 129 or 644µg; Acetaldehyde: 123 or 617µg). These doses
are in the range that had previously produced significant effects
in behavioral studies (Arizzi et al., 2003; Correa et al., 2003a,b;
Arizzi-LaFrance et al., 2006; McLaughlin et al., 2008). The vehicle
control procedure consisted of injections of 1.0ml of aCSF.
For the surgery, rats were anesthetized with a solution
(1.0ml/kg, IP) that contained ketamine and xylazine (10ml of
100mg/ml ketamine plus 0.75ml of 20mg/ml xylazine) (Phoenix
Pharmaceutical, Inc. St. Joseph, Mo).
SURGICAL PROCEDURE
For ICV injections, rats were implanted with unilateral guide
cannulae (10mm length 23 ga.). The stereotaxic coordinates for
lateral ventricle cannulation were as follows: AP −0.5mm (from
bregma), DL± 1.3mm lateral (from midline), and DV −3.0mm
ventral (from the surface of the skull). The incisor bar on the
stereotax was set to 0.0mm above the interaural line. All ani-
mals were singly housed after surgery, and were allowed 10 days
of recovery. Stainless steel stylets were kept in the guide cannu-
lae to maintain their integrity. Injections were made via 30 ga.
stainless steel injectors extending 1.5mm below the guide cannu-
lae. The injectors were attached to 10.0ml Hamilton syringes by
PE-10 tubing, and were driven by a Harvard Apparatus syringe
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pump (0.5ml / min, 1ml total volume). After the infusions injec-
tors were left in place for 1min to allow for diffusion of the drug,
after which the injectors were removed, stylets were replaced, and
animals were placed back into their home cages. The placements
of the injectors were verified histologically.
TISSUE PROCESSING AND c-Fos IMMUNOHISTOCHEMISTRY
Animals were anesthetized with CO2 and perfused transcardially
with 0.9% physiological saline followed by 3.7% paraformalde-
hyde, 120min after drug administration. The brains were
removed and post-fixed in formalin for 2 days. Thereafter, the
brains were cut into three coronal sections, ranging from 3–5mm
in thickness prior to being placed into tissue processing cassettes
for paraffin. The tissue cassettes were rinsed in water followed
by an EtOH rinse prior to immersion fixation. Paraffin embed-
ded coronal sections were cut (5–7µm) on a microtome (Leitz
Wetzlar, Spencer Scientific Co., New Hampshire) and immedi-
ately placed in a 40◦C water bath for mounting tissue on Plus
slides (Erie Scientific Co, New Hampshire) and allowed to air dry
for 24 h. Thereafter, the tissue slides underwent dehydration by
a series of three separate washes in citrosolve (2 × 7min), 100%
EtOH (2 × 7min), and 95% EtOH (2 × 7min). The slides were
rinsed in distilled water and incubated in a 0.3% H2O2 solu-
tion to block endogenous peroxidase activity. The slides were
washed (3 × 5min) in 0.1M phosphate buffer (PBS) (Dulbecco’s
phosphate buffered saline; pH 7.4; Sigma Chemical Co) fol-
lowed by a high pH antigen retrieval (DAKO, Denmark) incu-
bation for 15min. The slides were then allowed to cool and
washed in PBS prior to incubation in the primary antiserum.
c-Fos was visualized with a rabbit polyclonal anti-cFos (1:5000,
Calbiochem, Germany) for 24 h at room temperature. Following
the primary antibody incubation, the sections were washed in
PBS (3 × 5min) and incubated in the secondary, anti-rabbit
Horseraddish Peroxidase (HRP)-conjugate envision plus (DAKO,
Denmark) for 2 h at room temperature. Thereafter, sections were
washed and rinsed for 1–3min in 3,3′ diaminobenzidine chro-
magen (DAB) (brown). The sections were then rinsed in dis-
tilled water before the hydration series of rinses in 95% EtOH
(2 × 7min), EtOH (2 × 7min), and citrosolve (2 × 7min). The
slides were cover-slipped using Cytoseal 60 (Thermo Scientific) as
a mounting medium and then examined by light microscopy.
QUANTIFICATION OF c-Fos-LABELED CELL DENSITY
Tissue sections were imaged by optic microscopy (Nikon Eclipse
E600; Melville, NY) and photographed using SPOT software
(Diagnostic Instruments, Inc.). Selected areas of the brain were
outlined at low resolution (10×) using known landmarks (see
Figure 1 for schematic depictions of regions quantified), and
c-Fos-positive cells were identified and quantified at a higher res-
olution (20×) (0.125mm2/field) by light thresholding. A count-
ing grid (10 × 10) was superimposed on each photomicrograph
after background correction. The total density of c-Fos cells
were counted by a trained observer, who was unaware of the
experimental conditions in a minimum of three adjacent coro-
nal sections. The average value was used for statistical analysis.
This manual counting method was validated by comparing results
quantified with a modified automated ImageJ software program
FIGURE 1 | Schematic diagrams of relevant coronal levels and specific
brain regions depicted in Tables 1–6, and Figures 4, 5 [based on the
atlas of Paxinos and Watson (1998)]. The squares indicate the placement
of optical dissectors for counting c-Fos positive cells. Numbers represent
bregma at every coronal level. AcbC, accumbens core; AcbSh, accumbens
shell; BLA, basolateral amygdala; CA1, CA1 of the hippocampus; CeA,
central amygdala; Cg1, cingulate cortex 1; DG, dentate gyrus; DLS,
dorsolateral striatum; DMS, dorsomedial striatum; VLS, ventrolateral
striatum; IL, infralimbic cortex; LS, lateral septum; O, orbitofrontal cortex;
PrL, prelimbic cortex; Tu, lateral tubercle; VP, ventral pallidum.
(v. 1.42, National Institutes of Health sponsored image analy-
sis program) in a total of 20 pictures from different brain areas.
The correlation in the scores between both methods was r = 0.89
(p < 0.01).
STATISTICAL ANALYSIS
For each defined brain region and route of administration, cell
counts (c-Fos-positive cells per mm2) were compared across
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treatment groups by means of one way between-groups simple
ANOVA with five levels, followed by non-orthogonal planned
comparisons using the overall error term, comparing vehicle to
the other doses (Keppel, 1991). Significance was set at p < 0.05.
These analyses were conducted using a computerized statistical
package (SPSS). Figures 3, 5 are a representation of these data as
a percentage of change in relation to the corresponding vehicle
group for every brain structure. No additional statistical analyses
were performed.
RESULTS
Figure 1 shows schematic depictions of brain regions selected.
Name and abbreviations are listed in the figure legend.
EXPERIMENT 1. EFFECTS OF PERIPHERAL ADMINISTRATION OF EtOH
AND ACETALDEHYDE ON c-Fos IMMUNOREACTIVITY IN PREFRONTAL
CORTEX (PFC), BASAL GANGLIA AND LIMBIC AREAS
The overall one-way ANOVA yielded statistical significance for all
the brain areas tested but BLA and DG. These results are depicted
in Tables 1–3, respectively. The significance levels for the post hoc
analyses are shown in these tables only.
Thus, in the PFC the ANOVA results were as follows; Cg1
[F(4, 18) = 5.64, p < 0.01], PrL [F(4, 17) = 24.61, p < 0.01], IL
[F(4, 17) = 16.83, p < 0.01], and O [F(4, 17) = 5.55, p < 0.01].
The planned comparisons indicated that EtOH only induced c-
Fos expression in the PrL and O cortices and only at the lowest
dose (0.5 g/kg), while both doses of acetaldehyde significantly
Table 1 | Effect of acute IP administration of EtOH or acetaldehyde on c-Fos expression in PFC areas of rat brain.
Brain area Vehicle EtOH 0.5g/kg EtOH 2.5 g/kg Acetal 0.1 g/kg Acetal 0.5 g/kg
CELL COUNTS (per mm2) ± SEM
Cg1 418.6 ± 47.5 618.4± 70.4 678.9 ± 130.3 835.5 ± 129.7* 1156.2 ± 125.9**+##
PrL 267.0 ± 22.8 440.8 ± 53.1* 303.0 ± 14.8 546 ± 60.8** 881.0 ± 49.6**++##
IL 258.0 ± 13.7 372.0 ± 17.7 320.0 ± 16.5 508.8 ± 78.4** 787.0 ± 61.9**++##
O 318.0 ± 23.6 589.6 ± 86.3** 345 ± 25.9++ 560.0 ± 63.7** 620 ± 38.3**
Data are the mean number of c-Fos-positive cells (+SEM) per mm2 in the regions listed. (*p < 0.05, **p < 0.01 different from vehicle for the same brain region,
+p < 0.05, ++p < 0.01 different from the lower dose of the same drug, ##p < 0.01 different from the same dose of EtOH).
Table 2 | Effect of acute IP administration of EtOH or acetaldehyde on c-Fos expression in basal ganglia areas of rat brain.
Brain area Vehicle EtOH 0.5 g/kg EtOH 2.5 g/kg Acetal 0.1 g/kg Acetal 0.5 g/kg
CELL COUNTS (per mm2) ± SEM
AcbC 260.0 ± 66.5 486.8 ± 95.7* 264.8 ± 25.2+ 693.7 ± 103.8** 858.4 ± 22.8**##
AcbSh 242.6 ± 51.0 349.5 ± 19.7 325.6 ± 57.8 459.0 ± 55.9** 633.2 ± 71.3**+##
VLS 229.3 ± 9.6 456.5 ± 30.8* 547.3 ± 95.3** 594.1 ± 82.6** 648.6 ± 53.5**#
DLS 258.0 ± 17.2 449.3 ± 19.6** 335.4 ± 19.7 569.6 ± 60.1** 534.0 ± 50.1**
DMS 218.0 ± 29.5 462.4 ± 30.2** 405.8 ± 35.6* 559.3 ± 91.2** 562.0 ± 56.9**
VP 151.0 ± 47.0 296.8 ± 23.3* 304.0 ± 58.8* 328.4 ± 26.1* 417.5 ± 70.8**##
Data are the mean number of c-Fos-positive cells (+SEM) per mm2 in the regions listed. (*p < 0.05, **p < 0.01 different from vehicle for the same brain region,
+p < 0.05 different from the lower dose of the same drug, #p < 0.05, ##p < 0.01 different from the same dose of EtOH).
Table 3 | Effect of acute IP administration of EtOH or acetaldehyde on c-Fos expression in limbic areas of rat brain.
Brain area Vehicle EtOH 0.5 g/kg EtOH 2.5g/kg Acetal 0.1 g/kg Acetal 0.5 g/kg
CELL COUNTS (per mm2) ± SEM
Tu 118.0 ± 8.1 284.0 ± 28.1** 244.0 ± 17.5* 307.0 ± 36.5** 337.0 ± 61.7**
LS 124.0 ± 9.3 183.2 ± 18.5 194.4 ± 13.0* 263.0 ± 26.9** 398.0 ± 41.5**++##
BLA 66.0 ± 3.8 115.2 ± 29.1 44.8 ± 13.5 89.0 ± 14.2 135.0 ± 24.2
CeA 79.0 ± 16.9 118.4 ± 18.6 34.4 ± 16.9+ 99.0 ± 20.9 172.0 ± 23.2**++
CA1 74.0 ± 7.3 89.6 ± 7.2 114.4 ± 33.6 79.0 ± 7.7 182 ± 31.4**++##
DG 105.0 ± 15.3 128 ± 18.5 88.0 ± 32.4 90.4 ± 32.8 186.0 ± 38.9
Data are the mean number of c-Fos-positive cells (+SEM) per mm2 in the regions listed. (*p < 0.05, **p < 0.01 different from vehicle for the same brain region,
+p < 0.05, ++p < 0.01 different from the lower dose of the same drug, ##p < 0.01 different from the same dose of EtOH).
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induced c-Fos in all the cortical areas analyzed. Moreover,
acetaldehyde was more efficacious than EtOH in all the cortical
areas but O, since 0.5 g/kg acetaldehyde was statistically different
from 0.5 g/kg EtOH.
In the basal ganglia structures the overall one-way ANOVA’s
for all the different regions were significant. The F values were
as follows: AcbC [F(4, 17) = 12.87, p < 0.01], AcbSh [F(4, 17) =
6.96, p < 0.01], VLS [F(4, 17) = 6.28, p < 0.01], DLS [F(4, 17) =
10.94, p < 0.01], DMS [F(4, 17) = 8.48, p < 0.01], and VP
[F(4, 17) = 4.11, p < 0.05]. The planned comparisons indicated
that EtOH produced a significant increase at both doses in the
VLS, DMS, and VP, while in the AcbC and in the DLS only the
low dose induced c-Fos. Surprisingly, none of the EtOH doses
induced significantly c-Fos in the AcbSh. Acetaldehyde produced
significant induction of c-Fos in all the structures at both doses
and it was significantly more efficacious than EtOH at inducing
c-Fos in all the ventral areas of the striatum and in the VP, but not
in the dorsal areas of striatum (DLS and DMS). Figure 2 shows
representative microphotographs of PFC and Acb areas.
As pointed out above, in the limbic areas the one-wayANOVAs
were not significant in the BLA and in the DG. However, in
FIGURE 2 | c-Fos induction after IP administration of saline, ethanol
(0.5 g/kg) and acetaldehyde (0.5 g/kg). Low power images (10×) showing
PFC (left column) and Acb (right column). Scale bar = 100µm. ac, anterior
commissure; cc, corpus callosum.
the other areas the ANOVAs were significant; Tu [F(4, 17) = 5.89,
p < 0.01], LS [F(4, 17) = 8.14, p < 0.01], CeA [F(4, 17) = 11.48,
p < 0.01], and CA1 [F(4, 17) = 3.66, p < 0.05]. EtOH produced
a significant effect only in the Tu and in the LS, and these two
areas were also more sensitive to the effect of acetaldehyde (i.e.,
both doses produced an increase).
Overall, it seems that, among the EtOH groups, while 0.5 g/kg
increased c-Fos expression (although it was not always statistically
significant), 2.5 g/kg EtOH induced c-Fos only in some areas of
the striatum and limbic system, but it did not produce a larger
increase than the lower dose, thus possibly indicating a bipha-
sic effect of EtOH on c-Fos expression (see for example PrL and
O cortex, AcbC, and CeA). As for the acetaldehyde groups, in
general both doses increased c-Fos immunoreactivity at higher
levels than the EtOH groups, especially in cortical structures and
in both Acb subregions. Acetaldehyde was more efficacious than
EtOH at inducing c-Fos immunoreactivity, since EtOH at 0.5 g/kg
significantly induced c-Fos in 8 of the 16 areas, while 0.5 g/kg
acetaldehyde did so in 14 areas. Moreover, 0.5 g/kg acetaldehyde
was significantly different from 0.5 g/kg EtOH in 9 of the 16 areas.
The percentage change that this dose produced in relation to vehi-
cle for both drugs in all the structures studied is graphically shown
in Figure 3.
EXPERIMENT 2. EFFECTS OF CENTRAL ADMINISTRATION OF EtOH AND
ACETALDEHYDE ON c-Fos IMMUNOREACTIVITY IN PFC, BASAL
GANGLIA AND LIMBIC AREAS
The effects of ICV administration of EtOH or acetaldehyde on
c-Fos immunoreactivity are shown in Tables 4–6 for PFC, basal
ganglia and limbic areas, respectively. The results of the one-
way ANOVA for every brain area showed that the treatment
produced significant effects for all the areas studied. Thus in
the PFC; Cg1 [F(4, 18) = 11.28, p < 0.01], PrL [F(4, 19) = 10.88,
p < 0.01], IL [F(4, 19) = 15.41, p < 0.01], and O [F(4, 19) =
19.34, p < 0.01]. The planned comparisons indicated that EtOH
induced c-Fos only at the low dose (2.8µmoles) and only in
Cg1 and O. However, acetaldehyde produced significant effects in
all structures and at both doses. When comparing the low dose
(2.8µmoles) of EtOH with the same dose of acetaldehyde, it was
found that only in the Cg1 were there no differences between the
two drugs, although the higher dose (14µmoles) of acetaldehyde
induced c-Fos significantly compared with the effect of the high
dose of EtOH. In the rest of PFC areas both doses of acetalde-
hyde produced an increase compared to the corresponding dose
of EtOH.
The differences between ETOH and acetaldehyde were not so
pronounced in the basal ganglia or limbic structures. The one-
way ANOVA for the different structures indicated that the treat-
ment had a significant overall effect in all of them. The F values
were as follows: AcbC [F(4, 18) = 5.61, p < 0.01], in the AcbSh
[F(4, 18) = 3.24, p < 0.05], in the VLS [F(4, 17) = 3.12, p < 0.05],
in the DLS [F(4, 18) = 5.16, p < 0.01], in the DMS [F(4, 18) =
7.45, p < 0.01], and in the VP [F(4, 17) = 7.26, p < 0.01]. The
planned comparisons indicated that the low dose of EtOH sig-
nificantly induced c-Fos in both subregions of the Acb and also
in the projection area VP. However, the high dose of EtOH pro-
duced an increase only in the VP. The low dose of acetaldehyde
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FIGURE 3 | Percentage of change in c-Fos counts after IP administration of ethanol and acetaldehyde (0.5 g/kg) in relation to the saline vehicle group
for every brain structure. ∗p < 0.05, ∗∗p < 0.01 different from EtOH in that brain area.
Table 4 | Effect of acute ICV administration of EtOH or acetaldehyde on c-Fos expression in PFC areas of rat brain.
Brain area Vehicle EtOH 2.8 µmoles EtOH 14 µmoles Acetal 2.8 µmoles Acetal 14 µmoles
CELL COUNTS (per mm2) ± SEM
Cg1 307.0 ± 48.5 675.0 ± 167.5* 356.9 ± 28.2 884.9 ± 169.3** 1299.4 ± 131.8**+##
PrL 241.6 ± 20.0 295.2 ± 17.9 257.6 ± 26.0 521.6 ± 43.8**## 556.0 ± 99.9**##
IL 244.0 ± 36.0 281.6 ± 28.3 287.2 ± 31.5 539.5 ± 53.6**## 533.0 ± 19.3**##
O 318.4 ± 45.3 565.6 ± 50.5** 308.0 ± 42.0 610.4 ± 37.2** 764.0 ± 28.9**+##
Data are the mean number of c-Fos-positive cells (+SEM) per mm2 in the regions listed. (*p < 0.05, **p < 0.01 different from vehicle for the same brain region,
+p < 0.05 different from the lower dose of the same drug, ##p < 0.01 different from the same dose of EtOH).
Table 5 | Effect of acute ICV administration of EtOH or acetaldehyde on c-Fos expression in basal ganglia areas of rat brain.
Brain area Vehicle EtOH 2.8 µmoles EtOH 14 µmoles Acetal 2.8 µmoles Acetal 14 µmoles
CELL COUNTS (per mm2) ± SEM
AcbC 78.5 ± 31.5 409.0 ± 96.6* 371.0 ± 69.3 504.3 ± 162.1** 823.0 ± 150.7**##
AcbSh 108.4 ± 39.4 377.5 ± 120.9* 257.6 ± 60.7 398.5 ± 110.2* 503.8 ± 72.6**#
VLS 372.4 ± 21.7 489.8 ± 72.4 507.6 ± 47.7 616.3 ± 62.1** 468.4 ± 48.9
DLS 331.0 ± 15.7 409.4 ± 41.1 426.4 ± 18.1 435.3 ± 75.8 633.2 ± 48.4**++##
DMS 389.6 ± 26.1 366.5 ± 50.4 388.6 ± 48.8 500.1 ± 56.7**# 691.0 ± 49.9**+##
VP 208.8 ± 9.1 354.0 ± 20.4** 360.9 ± 15.1** 390.0 ± 40.0** 307.0 ± 36.2*+
Data are the mean number of c-Fos-positive cells (±SEM) per mm2 in the regions listed. (*p < 0.05; **p < 0.01 different from vehicle for the same brain region,
+p < 0.05; ++p < 0.01 different from the lower dose of the same drug, #p < 0.05, ##p < 0.01 different from the same dose of EtOH).
induced c-Fos in the ventral areas of the striatum (including both
Acb subregions and VLS) and in the VP, but not in the dor-
sal striatum. However there were no differences between EtOH
and acetaldehyde at this behaviorally relevant dose. Differences
between EtOH and acetaldehyde emerged only at the highest dose
in both subregions of the Acb and in both areas of the dorsal stria-
tum. See representative microphotographs of PFC and Acb areas
in Figure 4.
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Table 6 | Effect of acute ICV administration of EtOH or acetaldehyde on c-Fos expression in limbic areas of rat brain.
Brain area Vehicle EtOH 2.8 µmoles EtOH 14 µmoles Acetal 2.8 µmoles Acetal 14 µmoles
CELL COUNTS (per mm2) ± SEM
Tu 214.4 ± 27.2 369.6 ± 55.7* 241.6 ± 34.4+ 425.6 ± 27.9** 509.0 ± 46.6**##
LS 224.8 ± 28.6 248.0 ± 22.0 214.4 ± 13.0 325.6 ± 29.7*# 446.0 ± 31.4**++##
BLA 72.0 ± 6.8 144.0 ± 20.2* 196.0 ± 13.2** 187.0 ± 20.0* 146.0 ± 40.0**
CeA 60.8 ± 13.7 142.4 ± 27.1 238.4 ± 20.8**+ 193.6 ± 32.2** 125.0 ± 53.5#
CA1 91.2 ± 8.6 196.8 ± 12.2** 227.2 ± 13.1** 160.8 ± 31.2 259.0 ± 57.0**+
DG 89.6 ± 8.5 141.6 ± 14.8 243.2 ± 14.6**++ 199.2 ± 29.0** 168.0 ± 52.4*
Data are the mean number of c-Fos-positive cells (±SEM) per mm2 in the regions listed. (*p < 0.05, **p < 0.01 different from vehicle for the same brain region,
+p < 0.05, ++p < 0.01 different from the lower dose of the same drug, #p < 0.05, ##p < 0.01 different from the same dose of EtOH).
FIGURE 4 | c-Fos induction after ICV administration of vehicle,
ethanol (2.8µmoles) and acetaldehyde (2.8µmoles). Low power
images (10×) showing PFC (left column) and Acb (right column). Scale
bar = 100mm.
The one-way ANOVA for the limbic regions also demonstrated
a significant overall effect of the treatment in all areas stud-
ied. The F values were as follows: Tu [F(4, 19) = 9.39, p < 0.01],
LS [F(4, 19) = 13.01, p < 0.01], BLA [F(4, 19) = 5.72, p < 0.01],
CeA [F(4, 19) = 5.23, p < 0.01], CA1 [F(4, 19) = 5.60, p < 0.01],
and DG [F(4, 19) = 5.16, p < 0.01]. The planned comparisons
demonstrated that the low dose of EtOH produced signifi-
cant increases only in three of the areas (Tu, BLA, and CA1),
while the higher dose did so in both areas of the amyg-
dala and of the hippocampus. Acetaldehyde produced a more
robust increase, since at the low dose all areas but CA1 showed
increased c-Fos immunoreactivity compared to vehicle. At the
high dose all areas but CeA showed increased c-Fos counts.
Significant differences between both drugs were only seen in
the Tu and in the LS at both doses, while in the CeA the
high dose of EtOH produced an increase in c-Fos that was
significantly different from acetaldehyde, which at the highest
dose did not significantly induced c-Fos compared to vehicle.
The percentage change that 2.8µmoles of EtOH and acetalde-
hyde produced in relation to vehicle is graphically shown in
Figure 5.
DISCUSSION
The purpose of the present study was twofold: first, to compare
the pattern of c-Fos induction after EtOH and its metabolite
acetaldehyde were administered by two routes of administra-
tion that have been demonstrated to reveal differences in the
potency between both drugs, and second, we chose to study brain
areas with DArgic innervations because both drugs have demon-
strated to have effects on motor activity and motivated behaviors
regulated by DA. Thus, comparisons between behaviorally rele-
vant doses of both compounds after both routes of administra-
tion revealed the impact of each drug on different areas of the
brain.
EFFECTS OF PERIPHERAL ADMINISTRATION OF ETHANOL AND
ACETALDEHYDE
Overall, control values (saline or aCSF treatments) reflected com-
parable levels of c-Fos across the different routes of administra-
tion for all 16 brain regions quantified. In no case did EtOH
or acetaldehyde significantly reduce basal c-Fos levels. Peripheral
administration was the route that generated higher differences
between EtOH and acetaldehyde at the same dose. However, ICV
administration showed more contrasting effects between brain
areas, though less so between drugs. These results reflect the same
pattern of results found in behavioral studies (Arizzi et al., 2003;
Correa et al., 2003a,b; Arizzi-LaFrance et al., 2006; Chuck et al.,
2006; McLaughlin et al., 2008).
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FIGURE 5 | Percentage of change in c-Fos counts after ICV administration of ethanol and acetaldehyde (2.8µmoles) in relation to the aCSF vehicle
group for every brain structure. ∗p < 0.05, ∗∗p < 0.01 different from EtOH in that brain area.
Thus, as it can be seen in Figure 3, with the exception
of the O, PFC areas were significantly more responsive to
peripherally administered acetaldehyde than to EtOH (see pic-
tures in Figure 2). In Figure 3 it can also be appreciated that the
magnitude of change in c-Fos counts from vehicle at this dose
was significantly bigger for acetaldehyde in ventral basal ganglia
structures. However, these differences were less robust in lim-
bic structures, in which only LS and CA1 revealed a significantly
larger impact of acetaldehyde. Very few previous studies have
addressed the impact of peripheral acetaldehyde, either locally
formed or exogenously administered, on c-Fos immunoreactivity.
Expression of c-FosmRNA in the HPVwas increased after periph-
eral accumulation of acetaldehyde by blocking ALDH activity
with cyanamide and administering a dose of EtOH (1 g/kg) that
did not have this effect on its own (Kinoshita et al., 2002).
Kinoshita et al. (2002) did not explore any other brain area,
thus further comparisons with the present results are not possi-
ble. So far, there is only one previous study of direct peripheral
administration of acetaldehyde and c-Fos expression (Cao et al.,
2007). In that study a small dose of acetaldehyde (0.032 g/kg)
was administered also to Sprague-Dawley rats using intravenous
injections as the peripheral route of administration. In agreement
with the results of the 0.1 g/kg in the present study, 0.032 g/kg
did not produce a significant increase in the CeA, but in con-
trast to our results, it did not induce c-Fos in the AcbSh (Cao
et al., 2007). That dose was only able to increase c-Fos mRNA in
the PVTh, possibly because this dorsal thalamic region is min-
imally protected by the blood brain barrier (Ueno et al., 2000;
Cao et al., 2007). Moreover, the dose of acetaldehyde used in that
study seems to be very low, since it did not affect ambulation
or anxiety parameters (Cao et al., 2007). A dose of acetalde-
hyde of 0.1 g/kg IP, like the lowest one used in the present study,
was demonstrated to induce anxiety and reduce locomotion in
mice (Tambour et al., 2005; Escrig et al., 2012), and to slow
lever pressing in rats (McLaughlin et al., 2008), although in this
last study, higher doses of acetaldehyde (0.2 g/kg) were neces-
sary to produce a significant suppression of total lever pressing.
For EtOH, the required doses to slow lever pressing performance
and to suppress total amount of lever pressing were 0.8 and
1.6 g/kg (McLaughlin et al., 2008), indicating that the two drugs
also show differences in potency in terms of their behavioral
effects.
EFFECTS AFTER CENTRAL ADMINISTRATION OF ETHANOL AND
ACETALDEHYDE
After central administration, only 4 brain areas showed signif-
icant differences between EtOH and acetaldehyde at the lowest
dose of both drugs (2.8µmoles): two cortical structures, PrL
and IL (see pictures in Figure 4), DMS and LS. The highest
dose (14µmoles) of EtOH and acetaldehyde was the one that
lead to major differences between drugs after ICV administra-
tion (11 out of 16 structures). Interestingly, EtOH seems to
show a biphasic effect at this dose since in many structures
EtOH did not differ from vehicle. Acetaldehyde at the high dose
had a very different pattern because, in all but two structures,
there was still a significant increase in expression of c-Fos com-
pared to vehicle, and in several cases these changes were even
bigger than the ones produced by the lowest dose of acetalde-
hyde. Similar high doses have been used in previous studies
(Arizzi et al., 2003; Crankshaw et al., 2003) in which a dose of
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17.6µmoles of EtOH and acetaldehyde did not produce a sig-
nificant change in operant responding for food compared to
vehicle in a task that required minimal rates of responding, while
acetate, a metabolite of acetaldehyde, did suppress behavior at
these dose. Moreover, a dose of around 17µmoles of EtOH
administered ICV did not produce conditioned taste aversion
but it induced conditioned taste preference to a sweet solution
(Crankshaw et al., 2003). These data indicate that although it is
a high dose, the present 14µmoles dose does not affect behav-
ioral outcomes such as sustained attention, lever pressing, eating,
or taste related learning (Arizzi et al., 2003; Crankshaw et al.,
2003).
Two studies so far have measured c-Fos expression after ICV
EtOH administration in some areas of the brain (Crankshaw
et al., 2003; Larkin et al., 2010). Both of them have used higher
doses (790µg and 4mg; Crankshaw et al., 2003; Larkin et al.,
2010) than the high dose used in the present study (14µmoles =
644µg). The pattern of results found by those studies was differ-
ent from the present ones: positive increases in Cg cortex, (Larkin
et al., 2010), AcbSh and LS (Crankshaw et al., 2003), and no
increase in the CeA (Crankshaw et al., 2003; Larkin et al., 2010).
No previous study has assessed the involvement of acetaldehyde
in c-Fos expression after central administration. However, cata-
lase activity inhibition by aminotriazole (thus, blockade of brain
acetaldehyde formation), did not affect c-Fos expression in Acb
and CeA, after peripheral EtOH administration (Canales, 2004).
Those results point to an independent effect of EtOH on this
cellular parameter of activity.
IMPACT OF ETHANOL AND ACETALDEHYDE ON Acb-DA RELATED
FUNCTIONS
Among all the structures studied in the present work, the Acb
warrants additional examination. AcbC was revealed as the more
sensitive area to c-Fos induction after EtOH or acetaldehyde
with both routes of administration (see pictures in Figures 2, 4).
After peripheral administration, EtOH 0.5 g/kg produced a sig-
nificant induction of c-Fos immunoreactivity in AcbC, although
not in AcbSh. These results are somehow consistent with previous
studies from other laboratories. For example, after IP adminis-
tration of 1.0 or 2.5 g/kg of EtOH, also in Sprague-Dawley rats,
there was an increase on c-Fos expression in the general area
of the Acb (Canales, 2004). However, although in the present
study the increase in the AcbC was seen after the administra-
tion of a smaller dose (0.5 g/kg), we did not find a significant
increase at 2.5 g/kg, thus possibly pointing to a typical biphasic
effect of EtOH in this type of cellular markers in the Acb (Ibba
et al., 2009). In other studies c-Fos expression after 2.5 g/kg IP
of EtOH, did not produce an effect on AcbC but it did signif-
icantly induced c-Fos in AcbSh (47% increase) (Knapp et al.,
2001). In the present study 2.5 g/kg EtOH tended to induce c-
Fos in the AcbSh to a very similar magnitude (34%), although
this difference was not statistically significant. On the other hand,
after central administration of 2.8µmoles (129µg) of EtOH the
increases in c-Fos expression produced in both Acb subregions
(421% for the AcbC and 248% for AcbSh) reached statistical
significance (see Figure 5). In the only study of c-Fos expres-
sion after ICV EtOH administration that analyzed the Acb area
(Crankshaw et al., 2003), it was found a significant increase
(127%) in the AcbSh after a single injection of 790µg of EtOH.
In our study, the highest dose (644µg) of EtOH did not pro-
duce a statistically significant increase, although the percentage
of increase from vehicle was 375% for the AcbC and 138% for
the AcbSh, an increase very similar to the above mentioned
study. The effects of acetaldehyde in the Acb showed a signif-
icant increase at both doses and after both routes of adminis-
tration in both subregions (see pictures in Figures 2, 4). Both
doses of acetaldehyde increased c-Fos expression significantly in
AcbC (166 and 230%) and in AcbSh (89 and 161%). Moreover,
0.5 g/kg acetaldehyde produced a significantly higher increase
than the same dose of EtOH both in AcbC and in AcbSh (see
Figure 3). After central administration of acetaldehyde the pat-
tern of effects was the same as for peripheral administration.
There was a difference in efficacy at the highest dose; 14µmoles
of acetaldehyde, both in the AcbC and in the AcbSh, increased
c-Fos expression while 14µmoles of EtOH did not produce a
significant change. However, there was no difference in efficacy
between EtOH and acetaldehyde at a more behaviorally rele-
vant dose, 2.8µmoles (see Figure 5), as it was the case in food
reinforced lever pressing (Arizzi et al., 2003; McLaughlin et al.,
2008).
EtOH- and acetaldehyde-induced changes in c-Fos expres-
sion of DA target areas may be mediated by modulation of
DA release and DA receptor activation. Acetaldehyde has been
demonstrated to induce neuronal firing of DArgic neurons in the
ventral tegmental area (Foddai et al., 2004; Diana et al., 2008) and
to stimulate DA transmission in the Acb (Melis et al., 2007; Enrico
et al., 2009; Sirca et al., 2011; Deehan et al., 2013). Extracellular
regulated kinase (ERK) activation has been suggested as a post-
synaptic correlate of activated DA transmission (Acquas et al.,
2007), and acetaldehyde has been reported to elicit ERK phos-
phorylation in the rat Acb and extended amygdala, via DA D1
receptors (Vinci et al., 2010; Peana et al., 2011). Thus, periph-
eral intragrastric administration of EtOH (0.5–2.0 g/kg) increased
pERK in the AcbC and AcbS in a biphasic dose response way
(Ibba et al., 2009). A much lower dose of acetaldehyde (0.02 g/kg)
induced ERK phosphorylation also in AcbC, AcbSh (Vinci et al.,
2010; Peana et al., 2011). This is also important because ERK
seems to be necessary for the induction of c-Fos expression after
alcohol administration (Bachtell et al., 2002).
CONCLUSION
From the present study we can conclude that EtOH and acetalde-
hyde produce a general pattern of c-Fos induction in PFC, basal
ganglia, and limbic areas, most of which have a substantial DA
innervation (Fields, 2007; Ikemoto, 2007), at doses that are able
to affect motor activity and motivated behaviors (Arizzi et al.,
2003; Correa et al., 2003a,b; Arizzi-LaFrance et al., 2006; Chuck
et al., 2006; McLaughlin et al., 2008). Peripherally administered
acetaldehyde is more potent than EtOH at suppressing motor
behaviors (McLaughlin et al., 2008), and the same potency pat-
tern can be seen in relation to c-Fos expression (present paper).
The present results are also in accordance with the behavioral data
on locomotion and lever pressing after central administration.
Both drugs do not show big differences in efficacy or potency
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when injected in the ventricles (Arizzi et al., 2003; Correa et al.,
2003a; Arizzi-LaFrance et al., 2006; McLaughlin et al., 2008).
Thus, c-Fos can be used as a general marker of neural activity in
DA terminal areas, one which reflects the impact of EtOH and
acetaldehyde after different routes of administration on motor
and motivational functions.
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